Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | BCR | P11274 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590073 | 1.00 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5740934 | 0.96 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5740938 | 0.96 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL6381695 | 0.92 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5459297 | 0.92 | SRC (0.62) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL24010298 | 0.91 | SRC (0.60) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL6688486 | 0.91 | SRC (0.58) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL5253842 | 0.90 | SRC (0.60) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL4741681 | 0.89 | SRC (0.66) | SRCABL1BCREGFRERBB2 | |
| SCHEMBL4296487 | 0.89 | SRC (0.54) | SRCABL1BCREGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | STINGRAY THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-3350181-B1 | HER3 LIGANDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4259148-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | Stingray Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000068201-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2000-11-16 | — | — | WO | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | SRC 3638/4885ABL1 3449/4885BCR 2042/4885 |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | SRC 4226/4885ABL1 1758/4885BCR 3719/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | SRC 4226/4885ABL1 1758/4885BCR 3719/4885 |
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | ENPP1, ENPP3, PPP1R1B | SRC 1835/4885ABL1 1382/4885BCR 3867/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | SRC 3907/4885ABL1 1371/4885BCR 3899/4885 |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | SRC 3131/4885ABL1 1186/4885BCR 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.